Floatz logo

Neflamapimod

Cognitive Disorder

EIP Pharma IncSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Levodopa
Vanderbilt University Medical Center
Phase 4BB
Metformin
Fudan University
Phase 4BB
Quetiapine
Emory University
Phase 4BB

View all 50 →

Same molecule, other indications

Neflamapimod is also rated in:

Lewy body dementiaActive
BB
Indicative · Phase 2
66 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →
progressive non-fluent aphasiaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →